YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies.
YZY Bio is a biotechnology company that develops anti-tumor bispecific antibodies based on breakthrough discoveries in molecular biology, enabling patients with major diseases to obtain more efficient treatment solutions.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 4, 2022 | Series C | ¥200M | — | — | — | Detail |
| Sep 13, 2021 | Series B | ¥250M | 4 | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
TD Capital
|
— | Series B |
|
|
— | Series B |
|
|
— | Series B |
BGI Co-Win
|
— | Series B |